Literature DB >> 21289032

Quantitative role of LAL, NPC2, and NPC1 in lysosomal cholesterol processing defined by genetic and pharmacological manipulations.

Charina M Ramirez1, Benny Liu, Amal Aqul, Anna M Taylor, Joyce J Repa, Stephen D Turley, John M Dietschy.   

Abstract

Lipoprotein cholesterol taken up by cells is processed in the endosomal/lysosomal (E/L) compartment by the sequential action of lysosomal acid lipase (LAL), Niemann-Pick C2 (NPC2), and Niemann-Pick C1 (NPC1). Inactivation of NPC2 in mouse caused sequestration of unesterified cholesterol (UC) and expanded the whole animal sterol pool from 2,305 to 4,337 mg/kg. However, this pool increased to 5,408 and 9,480 mg/kg, respectively, when NPC1 or LAL function was absent. The transport defect in mutants lacking NPC2 or NPC1, but not in those lacking LAL, was reversed by cyclodextrin (CD), and the ED₅₀ values for this reversal varied from ~40 mg/kg in kidney to >20,000 mg/kg in brain in both groups. This reversal occurred only with a CD that could interact with UC. Further, a CD that could interact with, but not solubilize, UC still overcame the transport defect. These studies showed that processing and export of sterol from the late E/L compartment was quantitatively different in mice lacking LAL, NPC2, or NPC1 function. In both npc2(-/-) and npc1(-/-) mice, the transport defect was reversed by a CD that interacted with UC, likely at the membrane/bulk-water interface, allowing sterol to move rapidly to the export site of the E/L compartment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21289032      PMCID: PMC3284162          DOI: 10.1194/jlr.M013789

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  40 in total

Review 1.  The power of real-time PCR.

Authors:  Mark A Valasek; Joyce J Repa
Journal:  Adv Physiol Educ       Date:  2005-09       Impact factor: 2.288

Review 2.  Protein sensors for membrane sterols.

Authors:  Joseph L Goldstein; Russell A DeBose-Boyd; Michael S Brown
Journal:  Cell       Date:  2006-01-13       Impact factor: 41.582

Review 3.  A receptor-mediated pathway for cholesterol homeostasis.

Authors:  M S Brown; J L Goldstein
Journal:  Science       Date:  1986-04-04       Impact factor: 47.728

4.  Use of cyclodextrins for manipulating cellular cholesterol content.

Authors:  A E Christian; M P Haynes; M C Phillips; G H Rothblat
Journal:  J Lipid Res       Date:  1997-11       Impact factor: 5.922

5.  Receptor-mediated and bulk-phase endocytosis cause macrophage and cholesterol accumulation in Niemann-Pick C disease.

Authors:  Benny Liu; Chonglun Xie; James A Richardson; Stephen D Turley; John M Dietschy
Journal:  J Lipid Res       Date:  2007-05-02       Impact factor: 5.922

6.  Cyclodextrin overcomes the transport defect in nearly every organ of NPC1 mice leading to excretion of sequestered cholesterol as bile acid.

Authors:  Benny Liu; Charina M Ramirez; Anna M Miller; Joyce J Repa; Stephen D Turley; John M Dietschy
Journal:  J Lipid Res       Date:  2009-11-18       Impact factor: 5.922

7.  Three-pool model of the long-term turnover of plasma cholesterol in man.

Authors:  D S Goodman; R P Noble; R B Dell
Journal:  J Lipid Res       Date:  1973-03       Impact factor: 5.922

8.  Solubilization and localization of cholesteryl oleate in egg phosphatidylcholine vesicles. A carbon 13 NMR study.

Authors:  J A Hamilton; D M Small
Journal:  J Biol Chem       Date:  1982-07-10       Impact factor: 5.157

Review 9.  Central nervous system: cholesterol turnover, brain development and neurodegeneration.

Authors:  John M Dietschy
Journal:  Biol Chem       Date:  2009-04       Impact factor: 3.915

10.  Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression.

Authors:  Cristin D Davidson; Nafeeza F Ali; Matthew C Micsenyi; Gloria Stephney; Sophie Renault; Kostantin Dobrenis; Daniel S Ory; Marie T Vanier; Steven U Walkley
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

View more
  37 in total

1.  Therapeutic potential of cyclodextrins in the treatment of Niemann-Pick type C disease.

Authors:  Benny Liu
Journal:  Clin Lipidol       Date:  2012-06

2.  Cyclodextrin mediates rapid changes in lipid balance in Npc1-/- mice without carrying cholesterol through the bloodstream.

Authors:  Anna M Taylor; Bing Liu; Yelenis Mari; Benny Liu; Joyce J Repa
Journal:  J Lipid Res       Date:  2012-08-14       Impact factor: 5.922

3.  Hepatic entrapment of esterified cholesterol drives continual expansion of whole body sterol pool in lysosomal acid lipase-deficient mice.

Authors:  Amal Aqul; Adam M Lopez; Kenneth S Posey; Anna M Taylor; Joyce J Repa; Dennis K Burns; Stephen D Turley
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-08-21       Impact factor: 4.052

Review 4.  Molecular pathways for intracellular cholesterol accumulation: common pathogenic mechanisms in Niemann-Pick disease Type C and cystic fibrosis.

Authors:  Nicholas L Cianciola; Cathleen R Carlin; Thomas J Kelley
Journal:  Arch Biochem Biophys       Date:  2011-09-05       Impact factor: 4.013

5.  Sterol transfer between cyclodextrin and membranes: similar but not identical mechanism to NPC2-mediated cholesterol transfer.

Authors:  Leslie A McCauliff; Zhi Xu; Judith Storch
Journal:  Biochemistry       Date:  2011-08-04       Impact factor: 3.162

6.  Systemic administration of 2-hydroxypropyl-β-cyclodextrin to symptomatic Npc1-deficient mice slows cholesterol sequestration in the major organs and improves liver function.

Authors:  Adam M Lopez; Sandi J Terpack; Kenneth S Posey; Benny Liu; Charina M Ramirez; Stephen D Turley
Journal:  Clin Exp Pharmacol Physiol       Date:  2014-10       Impact factor: 2.557

Review 7.  The Extending Spectrum of NPC1-Related Human Disorders: From Niemann-Pick C1 Disease to Obesity.

Authors:  Amel Lamri; Marie Pigeyre; William S Garver; David Meyre
Journal:  Endocr Rev       Date:  2018-04-01       Impact factor: 19.871

8.  Niemann-Pick C1-deficient mice lacking sterol O-acyltransferase 2 have less hepatic cholesterol entrapment and improved liver function.

Authors:  Adam M Lopez; Ryan D Jones; Joyce J Repa; Stephen D Turley
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-06-07       Impact factor: 4.052

Review 9.  Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease.

Authors:  Elizabeth A Ottinger; Mark L Kao; Nuria Carrillo-Carrasco; Nicole Yanjanin; Roopa Kanakatti Shankar; Marjo Janssen; Marcus Brewster; Ilona Scott; Xin Xu; Jim Cradock; Pramod Terse; Seameen J Dehdashti; Juan Marugan; Wei Zheng; Lili Portilla; Alan Hubbs; William J Pavan; John Heiss; Charles H Vite; Steven U Walkley; Daniel S Ory; Steven A Silber; Forbes D Porter; Christopher P Austin; John C McKew
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

10.  Cholesterol homeostatic responses provide biomarkers for monitoring treatment for the neurodegenerative disease Niemann-Pick C1 (NPC1).

Authors:  Brett Tortelli; Hideji Fujiwara; Jessica H Bagel; Jessie Zhang; Rohini Sidhu; Xuntian Jiang; Nicole M Yanjanin; Roopa Kanakatti Shankar; Nuria Carillo-Carasco; John Heiss; Elizabeth Ottinger; Forbes D Porter; Jean E Schaffer; Charles H Vite; Daniel S Ory
Journal:  Hum Mol Genet       Date:  2014-06-25       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.